MX2024004478A - Sales de r-ketamina y metodos de uso de las mismas. - Google Patents

Sales de r-ketamina y metodos de uso de las mismas.

Info

Publication number
MX2024004478A
MX2024004478A MX2024004478A MX2024004478A MX2024004478A MX 2024004478 A MX2024004478 A MX 2024004478A MX 2024004478 A MX2024004478 A MX 2024004478A MX 2024004478 A MX2024004478 A MX 2024004478A MX 2024004478 A MX2024004478 A MX 2024004478A
Authority
MX
Mexico
Prior art keywords
ketamine
salts
methods
salt
salt forms
Prior art date
Application number
MX2024004478A
Other languages
English (en)
Spanish (es)
Inventor
Terence Alfred Kelly
Mouhannad Jumaa
Original Assignee
Perception Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perception Neuroscience Inc filed Critical Perception Neuroscience Inc
Publication of MX2024004478A publication Critical patent/MX2024004478A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2024004478A 2021-10-12 2022-10-12 Sales de r-ketamina y metodos de uso de las mismas. MX2024004478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163254878P 2021-10-12 2021-10-12
PCT/US2022/046412 WO2023064363A1 (en) 2021-10-12 2022-10-12 R-ketamine salts and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2024004478A true MX2024004478A (es) 2024-07-01

Family

ID=84331621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004478A MX2024004478A (es) 2021-10-12 2022-10-12 Sales de r-ketamina y metodos de uso de las mismas.

Country Status (8)

Country Link
US (1) US20240336556A1 (cg-RX-API-DMAC10.html)
EP (1) EP4416126A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024539623A (cg-RX-API-DMAC10.html)
CN (1) CN118647595A (cg-RX-API-DMAC10.html)
CA (1) CA3234818A1 (cg-RX-API-DMAC10.html)
IL (1) IL312041A (cg-RX-API-DMAC10.html)
MX (1) MX2024004478A (cg-RX-API-DMAC10.html)
WO (1) WO2023064363A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1444041A2 (en) 2001-09-21 2004-08-11 Solvias AG Sealing system with flow channels
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
WO2019065900A1 (ja) 2017-09-27 2019-04-04 国立大学法人千葉大学 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr-ケタミンおよびその誘導体
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
US20220110889A1 (en) 2018-12-27 2022-04-14 National University Corporation Chiba University R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
KR20220002905A (ko) * 2019-03-25 2022-01-07 더글라스 파머수티클스 리미티드 서방형 약학 제제
EP3968979B1 (en) * 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
GB201912505D0 (en) * 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation

Also Published As

Publication number Publication date
US20240336556A1 (en) 2024-10-10
CA3234818A1 (en) 2023-04-20
CN118647595A (zh) 2024-09-13
WO2023064363A9 (en) 2024-02-15
WO2023064363A1 (en) 2023-04-20
EP4416126A1 (en) 2024-08-21
IL312041A (en) 2024-06-01
JP2024539623A (ja) 2024-10-29

Similar Documents

Publication Publication Date Title
MX2025011899A (es) Compuestos de pirido[4,3-d]pirimidina
GEAP202315746A (en) Protein tyrosine phosphatase inhibitors
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
GEAP202516802A (en) Protac chimeric compound, preparation method thereof and use thereof
EA201991615A1 (ru) Композиция маннуроновой дикислоты
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
ZA202304541B (en) Cdk inhibitors and their use as pharmaceuticals
WO2025014877A3 (en) Triazolo wrn inhibitors
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
WO2024254511A3 (en) Wrn inhibitors
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
MX2023014547A (es) Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3).
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
MX2024012014A (es) Formas de sales de mesembrina
ZA202400823B (en) Inhibitors of transglutaminases
WO2023244996A3 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
MX2025007158A (es) Inhibidores de gmp?amp sintasa ciclica y sus usos
MX2025011564A (es) Formas cristalinas de un compuesto para la degradacion dirigida del receptor de androgenos
WO2024215923A3 (en) Cyclic vinyl sulfone wrn inhibitors
WO2024086789A3 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
GEAP202516820A (en) Prmt5-mta inhibitor
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.